Figure 1
From: Platform process will give platform product - Can we afford it?
(Clockwise direction) a) Viability comparison between control (mAb1-4) and mAb5 and 6. b) Viability comparison between platform and modified process for mAb5 and 6. c) Cell count comparison and d) Lactate comparison between cell line technology 1 and 2. As expected, PQ profiles between these two clones were very different.